AzTrials
AzTrials

Non-Small Cell Lung CancerPhase 3SKYSCRAPER-01NCT04294810

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

A Phase 3 study testing Atezolizumab and Tiragolumab in people with Non-Small Cell Lung Cancer, run by Hoffmann-La Roche at 134 sites in 23 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Non-Small Cell Lung Cancer
What is being tested?
Atezolizumab and Tiragolumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
620 participants
Where
134 sitesin 23 countries
Study dates
4 Mar 2020to 30 Dec 2025
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Who cannot join

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
Show all 11Show fewer
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

Trial locations and contacts

134 sites in 23 countries.

134 sites in 23 countries

China18 sites

  • Beijing Cancer Hospital

    Beijing, 100142

  • The First Hospital of Jilin University

    Changchun, 130021

  • West China Hospital, Sichuan University

    Chengdu, 610041

  • Chongqing Cancer Hospital

    Chongqing, 400030

  • Fujian Cancer Hospital

    Fuzhou, 350014

  • Hainan General Hospital

    Haikou, 570311

  • Sir Run Run Shaw Hospital Zhejiang University

    Hangzhou, 310016

  • Harbin Medical University Cancer Hospital

    Harbin, 150081

  • Jinan Central Hospital

    Jinan, 250013

  • Meizhou People's Hospital

    Meizhou, 514031

  • The 1st Affiliated Hospital of Nanchang Unversity

    Nanchang, 330200

  • Nantong Tumor Hospital

    Nantong, 226361

  • Zhongshan Hospital Fudan University

    Shanghai, 200032

  • Fudan University Shanghai Cancer Center

    Shanghai, 200120

  • Shanghai Pulmonary Hospital

    Shanghai, 200433

  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi'an, 710061

  • The First Affiliated Hospital of Xiamen University

    Xiamen, 361003

  • Zhejiang Cancer Hospital

    Zhejiang, 310022

Other trials in China

Japan12 sites

  • Aichi Cancer Center

    Aichi, 464-8681

  • National Cancer Center Hospital East

    Chiba, 277-8577

  • Kyushu University Hospital

    Fukuoka, 812-8582

  • Sendai Kousei Hospital

    Miyagi, 980-0873

  • Niigata Cancer Center Hospital

    Niigata, 951-8566

  • Osaka International Cancer Institute

    Osaka, 541-8567

  • Kindai University Hospital

    Osaka, 589-8511

  • Saitama Cancer Center

    Saitama, 362-0806

  • NHO Kinki-Chuo Chest Medical Center

    Sakaishi, 591-8555

  • Shizuoka Cancer Center

    Shizuoka, 411-8777

  • National Cancer Center Hospital

    Tokyo, 104-0045

  • The Cancer Institute Hospital of JFCR

    Tokyo, 135-8550

Other trials in Japan

South Korea12 sites

  • Chungbuk National University Hospital

    Cheongju-si, 28644

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620

  • Ajou University Medical Center

    Gyeonggi-do, 16499

  • Gachon University Gil Medical Center

    Incheon, 21565

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, 58128

  • Seoul National University Hospital

    Seoul, 03080

  • Kangbuk Samsung Medical Center

    Seoul, 03181

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722

  • Asan Medical Center

    Seoul, 05505

  • Korea University Guro Hospital

    Seoul, 08308

  • Samsung Medical Center

    Seoul, 6351

  • St. Vincent's Hospital

    Suwon, 442-723

Other trials in South Korea

Italy10 sites

  • Azienda Ospedaliera San Giuseppe Moscati

    Avellino, Campania, 83100

  • Irccs Istituto Europeo di Oncologia (IEO)

    Milan, Lombardy, 20141

  • Asst Di Monza

    Monza, Lombardy, 20900

  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale

    Naples, Campania, 80131

  • Azienda Sanitaria Ospedaliera S Luigi Gonzaga

    Orbassano, Piedmont, 10043

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, 35128

  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

    Perugia, Umbria, 06156

  • Azienda Ospedaliera San Camillo Forlanini

    Rome, Lazio, 00151

  • Policlinico Universitario "Agostino Gemelli"

    Rome, Lazio, 00168

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, 20089

Other trials in Italy

United States9 sites

  • Rocky Mountain Cancer Center - Denver

    Denver, Colorado, 80220

  • Virginia Cancer Specialists (Fairfax) - USOR

    Fairfax, Virginia, 22031

  • SCRI Oncology Partners

    Nashville, Tennessee, 37203

  • Yale Cancer Center

    New Haven, Connecticut, 06520

  • US oncology research at Minnesota Oncology

    Saint Paul, Minnesota, 55102

  • Onc & Hem Assoc SW Virginia

    Salem, Virginia, 24153

  • SCRI Florida Cancer Specialists North

    St. Petersburg, Florida, 33705

  • SCRI Florida Cancer Specialists PAN

    Tallahassee, Florida, 32308

  • Northwest Cancer Specialists - Vancouver

    Vancouver, Washington, 98684

Other trials in United States

Spain8 sites

  • Hospital General Universitario de Alicante

    Alicante, 03010

  • Hospital Universitario Germans Trias i Pujol

    Badalona, Barcelona, 08916

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035

  • Hospital 12 de Octubre

    Madrid, 28041

  • Hospital Universitario Puerta de Hierro - Majadahonda

    Madrid, 28222

  • Hospital Universitario Virgen del Rocío

    Madrid, 41013

  • Hospital Regional Universitario de Malaga

    Málaga, 29010

  • Hosp Clinico Univ Lozano Blesa

    Zaragoza, 50009

Other trials in Spain

Taiwan8 sites

  • Chang Gung Memorial Hospital - Linkou Branch

    Guishan Dist., 33305

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, 807

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, 83301

  • Taipei Medical University ?Shuang Ho Hospital

    New Taipei City, 23561

  • Taichung Veterans General Hospital

    Taichung, 407

  • National Cheng Kung Uni Hospital

    Tainan, 704

  • Taipei Veterans General Hospital

    Taipei, 112

  • National Taiwan University Hospital

    Zhongzheng Dist., 10048

Other trials in Taiwan

Germany6 sites

  • Krankenhaus Nordwest

    Frankfurt, 60488

  • LungenClinic Großhansdorf GmbH

    Großhansdorf, 22927

  • Krankenhaus Martha-Maria Halle-Doelau gGmbH

    Halle, 06120

  • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein

    Löwenstein, 74245

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, 48153

  • Klinik Schillerhöhe

    Stuttgart, 70376

Other trials in Germany

Turkey (Türkiye)6 sites

  • Adana Baskent University Hospital

    Adana, 01120

  • Hacettepe University Medical Faculty

    Ankara, 06100

  • Istanbul University Cerrahpasa Faculty of Medicine

    Istanbul, 34098

  • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi

    Izmir, 35110

  • Goztepe Prof.Dr. Suleyman Yalcin City Hospital

    Kadiköy, 34722

  • Inonu University Medical Faculty of Medicine

    Malatya, 44280

Other trials in Turkey (Türkiye)

Russia5 sites

  • Main Military Clinical Hospital named after N.N. Burdenko

    Moscow, Moscow Oblast, 105229

  • MEDSI Clinical Hospital on Pyatnitsky Highway

    Moscow, Moscow Oblast, 143422

  • Institute of Oncology

    Saint Petersburg, Sankt-Peterburg, 189646

  • St. Petersburg Med Univ

    Saint Petersburg, Sankt-Peterburg, 197089

  • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)

    Saint Petersburg, Sankt-Peterburg, 197758

Other trials in Russia

Mexico4 sites

  • Health Pharma Professional Research

    CD Mexico, Mexico CITY (federal District), 03810

  • Cryptex Investigacion Clinica SA de CV

    México, Mexico CITY (federal District), 06100

  • AVIX Investigación Clínica S.C

    Monterrey, Nuevo León, 64710

  • Cuidados oncologicos

    Querétaro City, Querétaro, 76000

Other trials in Mexico

Peru4 sites

  • Instituto Regional de Enfermedades Neoplásicas del Sur

    Arequipa, 5154

  • Instituto Nacional de Enfermedades Neoplasicas

    Lima, 15038

  • Clinica Internacional, Sede San Borja

    Lima, Lima 41

  • Clinica Ricardo Palma

    San Isidro, Lima 27

Other trials in Peru

Thailand4 sites

  • Chulalongkorn Hospital

    Bangkok, 10330

  • Ramathibodi Hospital

    Bangkok, 10400

  • Faculty of Med. Siriraj Hosp.

    Bangkok, 10700

  • Songklanagarind Hospital

    Songkhla, 90110

Other trials in Thailand

Australia3 sites

  • Austin Hospital Olivia Newton John Cancer Centre

    Heidelberg, Victoria, 3084

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, 3000

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, 4102

Other trials in Australia

Austria3 sites

  • Ordensklinikum Linz Elisabethinen

    Linz, 4020

  • Klinik Penzing

    Vienna, 1140

  • Krankenhaus Nord - Klinik Floridsdorf

    Vienna, 1210

Other trials in Austria

Greece3 sites

  • Sotiria Hospital

    Athens, 104 31

  • Metropolitan Hospital

    Athens, 185 47

  • University Hospital of Larissa

    Larissa, 411 10

Other trials in Greece

Hungary3 sites

  • Orszagos Koranyi TBC es Pulmonologiai Intezet

    Budapest, 1121

  • Matrai Gyogyintezet

    Mátraháza, 3233

  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház

    Szolnok, 5004

Other trials in Hungary

Netherlands3 sites

  • Ziekenhuis Gelderse Vallei

    Ede, 6716 RP

  • Medisch Centrum Leeuwarden

    Leeuwarden, 8934 AD

  • Hagaziekenhuis, locatie Leyweg

    The Hague, 2545 AA

Other trials in Netherlands

Poland3 sites

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, 80-214

  • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie

    Olsztyn, 10-357

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu

    Poznan, 60-569

Other trials in Poland

Switzerland3 sites

  • Inselspital Bern

    Bern, 3010

  • CHUV

    Lausanne, 1011

  • HOCH Health Ostschweiz, Kantonsspital St. Gallen

    Sankt Gallen, 9000

Other trials in Switzerland

Ukraine3 sites

  • City Clinical Hospital #4

    Dnipropetrovsk, 49102

  • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council

    Kryvyi Rih, 50048

  • Uzhgorod Nat. University Central Municip Hosp

    Uzhhorod, 88000

Other trials in Ukraine

Brazil2 sites

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, 14784-400

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, 98700-000

Other trials in Brazil

Serbia2 sites

  • Clinical Center of Serbia

    Belgrade, 11000

  • University Hospital Medical Center Bezanijska kosa

    Belgrade, 11080

Other trials in Serbia

About this study

Official title: A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Being tested
Atezolizumab, Tiragolumab, Matching Placebo
Medical subject headings
Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AtezolizumabDrug

    Also called Tecentriq

    Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

  • TiragolumabDrug

    Also called MTIG7192A

    Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

  • Matching PlaceboDrug

    Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Study groups in NCT04294810
Study groupRoleWhat they receive
Tiragolumab + AtezolizumabExperimentalParticipants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Receives: Drug: Atezolizumab; Drug: Tiragolumab
Placebo + AtezolizumabPlacebo comparatorParticipants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Receives: Drug: Atezolizumab; Drug: Matching Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set

    Measured: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)

  2. Overall Survival (OS) in the Primary Analysis Set

    Measured: From randomization to death from any cause (up to approximately 59 months)

  3. Percentage of Participants With Adverse Events (AEs)

    Measured: Up to approximately 59 months

  4. Percentage of Participants With Cytokine-Release Syndrome (CRS)

    Measured: Up to approximately 59 months

Secondary outcomes (7)

  1. Investigator-Assessed PFS in the Secondary Analysis Set

    Measured: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)

  2. OS in the Secondary Analysis Set

    Measured: From randomization to death from any cause (up to approximately 59 months)

  3. Investigator-Assessed Confirmed Objective Response Rate (ORR)

    Measured: From randomization up to approximately 59 months

  4. Investigator-Assessed Duration of Response (DOR)

    Measured: From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 59 months)

  5. Investigator-Assessed PFS Rates at 6 Months and 12 Months

    Measured: 6 months, 12 months

  6. OS Rates at 12 Months and 24 Months

    Measured: 12 months, 24 months

  7. Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score

    TTCD using EORTC QLQ-C30 is an initial 10-point decrease in global health status (GHS)/quality of life (QoL) and functioning from baseline that must be held for at least two consecutive assessments or an initial clinically meaningful decrease above baseline followed by death. EORTC QLQ-C30: a self-reported measure, consisting of 30 questions that assess 5 aspects of participants functioning (physical, emotional, role, cognitive and social), 3 symptom scales (fatigue, nausea and vomiting and pain), GHS and QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) with a recall period of the previous week. Functioning items are scored on a 4-point scale: 1=Not at all to 4=Very much, with higher score indicating worse outcome. Symptom items (GHS and QoL) are scored on a 7-point scale: 1=Very poor to 7=Excellent. Scores will be linearly transformed with a minimum score of 0 and maximum score of 100. Higher score indicates better outcome.

    Measured: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 59 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Mar 2020
  2. Study start4 Mar 2020
  3. Primary completion30 Dec 2025
  4. Study completion30 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
620 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04294810
Sponsor's protocol ID
GO41717
Other IDs
2019-002925-31, 2022-502482-17-00, 2019
Acronym
SKYSCRAPER-01
Status last verified
Jan 2026
First submitted
2 Mar 2020
Last updated
30 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing

Publications

  • Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon BJ, Gumus M, Erman M, Bondarenko I, Kim DW, Felip E, Morabito A, Bryl M, Urban L, Nosaki K, Reck M, Meng R, Stroud C, Kundu P, Wen X, Patil NS, Huang M, Troutman S, Matheny C, Cho BC. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. J Clin Oncol. 2026 Sep;44(25):2400-2408. doi: 10.1200/JCO-25-02777. Epub 2026 Jul 27.

    PubMed 42507968

  • Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. J Clin Oncol. 2026 Sep 10;44(26):2507-2516. doi: 10.1200/JCO-26-00327. Epub 2026 Jul 27.

    PubMed 42507965

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Atezolizumab and Tiragolumab in people with Non-Small Cell Lung Cancer, run by Hoffmann-La Roche at 134 sites in 23 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 134 sites in China, Japan, South Korea, Italy, United States and 18 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04294810, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in